MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
BioNano Genomics Interest Expense 2011-2026 | BNGO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | -10.1 M | -20.5 M | 298 K | 927 K | 2.52 M | 2.29 M | 1.38 M | 591 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 M | -20.5 M | -1.86 M |
Quarterly Interest Expense BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -219 K | 676 K | 5.08 M | - | -697 K | 363 K | -1.36 M | - | -45 K | -330 K | 76 K | - | 73 K | 74 K | 77 K | - | 2 K | 210 K | 603 K | - | 589 K | 561 K | 761 K | - | 578 K | 645 K | 273 K | - | 404 K | 408 K | 302 K | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.08 M | -1.36 M | 370 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
8.26 M | $ 15.15 | -2.51 % | $ 1.96 B |  USA |
 |
Biomerica
BMRA
|
367 | $ 2.16 | - | $ 4.96 M | USA |
 |
Bioventus
BVS
|
-1.45 M | $ 9.16 | 0.11 % | $ 610 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 7.7 | -0.77 % | $ 30.7 M | Israel |
 |
DexCom
DXCM
|
177 M | $ 66.84 | 0.36 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.67 | 2.02 % | $ 504 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 165.89 | 4.21 % | $ 8.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 99.99 | -1.27 % | $ 8.25 B |  Irlanda |
 |
Illumina
ILMN
|
-292 M | $ 126.2 | 0.17 % | $ 20.1 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 165.64 | -0.27 % | $ 28.5 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 3.75 | 8.38 % | $ 2.01 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 75.63 | 1.87 % | $ 5.1 B | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.69 | -1.31 % | $ 7.41 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 466.8 | 1.32 % | $ 13.5 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.68 | 1.52 % | $ 433 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.18 | -1.49 % | $ 385 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 197.37 | 1.47 % | $ 19.4 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 110.22 | 8.05 % | $ 4.35 B | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.19 | 5.31 % | $ 826 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 266.02 | -0.04 % | $ 22.1 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.39 | - | $ 417 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.77 | -1.15 % | $ 995 M | USA |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-1 K | $ 27.24 | 2.41 % | $ 35.4 M | USA |
 |
Personalis
PSNL
|
24 K | $ 7.7 | -1.03 % | $ 456 M | USA |